Overview of Dr. McCloskey
Dr. James McCloskey is an oncologist in Hackensack, NJ and is affiliated with multiple hospitals in the area, including Hackensack Meridian Health Hackensack University Medical Center and Hackensack Meridian Health Jersey Shore University Medical Center. He received his medical degree from Georgetown University School of Medicine and has been in practice 9 years. He is one of 130 doctors at Hackensack Meridian Health Hackensack University Medical Center and one of 41 doctors at Hackensack Meridian Health Jersey Shore University Medical Center who specialize in Oncology. He has more than 30 publications and over 500 citings.
Office
92 2nd Street
Hackensack, NJ 07601- Is this information wrong?
Education & Training
MedStar Health/Georgetown University HospitalFellowship, Hematology and Medical Oncology, 2011 - 2014- MedStar Health/Georgetown University HospitalResidency, Internal Medicine, 2008 - 2011
Georgetown University School of MedicineClass of 2008
Certifications & Licensure
NJ State Medical License 2014 - 2025
DC State Medical License 2008 - 2024
VA State Medical License 2008 - 2016
Clinical Trials
- Safety and Anti-Disease Activity of Oral Tosedostat (CHR-2797) in Elderly Subjects With Refractory or Relapsed AML Start of enrollment: 2009 Oct 01
- Single Agent and Combined Inhibition After Allogeneic Stem Cell Transplant Start of enrollment: 2019 Mar 08
- Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML Start of enrollment: 2018 Aug 15
- Join now to see all
Publications & Presentations
PubMed
- Phase 2 study of add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib: final results.Abdulraheem Yacoub, Uma Borate, Raajit K Rampal, Haris Ali, Eunice S Wang, Aaron T Gerds, Gabriela Hobbs, Marina Kremyanskaya, Elliott Winton, Casey O'Connell, Swati G...> ;Blood Advances. 2024 Mar 26
- 3 citationsOral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised...Garcia-Manero, G., McCloskey, J., Griffiths, E., Yee, K., Zeidan, A., Al-Kali, A., Deeg, H., Patel, P., Sabloff, M., Keating, M., Zhu, N., Gabrail, N., Fazal, S., Maly...> ;The Lancet. Haematology. 2024 Jan 1
- Aspacytarabine for the treatment of patients with AML unfit for intensive chemotherapy: a phase 2 study.Altman, J., Zuckerman, T., Koprivnikar, J., McCloskey, J., Kota, V., Keng, M., Frankfurt, O., Abaza, Y., Bixby, D., Emadi, A., Burch, M., Bhatnagar, B., Luger, S., Per...> ;Blood Advances. 2023 Dec 26
- Join now to see all
Abstracts/Posters
- Combined Venetoclax and Hypomethylating Agent (HMA) Therapy Induces High Response Rates in Patients with Myelodysplastic Syndrome Including Patients Previously Failing...James McCloskey, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Pharmacokinetic Exposure Equivalence and Preliminary Efficacy and Safety from a Randomized Cross over Phase 3 Study (ASCERTAIN study) of an Oral Hypomethylating Agent ...James McCloskey, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Lectures
- Blinatumomab in Combination with Tyrosine Kinase Inhibitors Safely and Effectively Induces Rapid, Deep, and Durable Molecular Responses in Relapsed and Refractory Phil...61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Molecular Epidemiologic Associations in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) within the United States2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
Opinion: The Pandemic and the RNA Sequencing GapSeptember 1st, 2021
Hospital Affiliations
Hackensack Meridian Health Hackensack University Medical CenterHackensack, New Jersey
Hackensack Meridian Health Jersey Shore University Medical CenterNeptune, New Jersey
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
